A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522403-17-00

Enrollment

Registered

2026-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nummular Dermatitis

Brief summary

1. Percentage of participants achieving endpoint reduction from baseline at Week 24.

Detailed description

1. Percentage of participants with Pruritus NRS ≥4 at baseline achieving a ≥4-point improvement in Pruritus NRS score from baseline at Week 24, 2. Absolute change from baseline in DLQI to Week 24.

Interventions

DRUGPlacebo

DRUGEbglyss 250 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Percentage of participants achieving endpoint reduction from baseline at Week 24.	—

Secondary

Measure	Time frame
1. Percentage of participants with Pruritus NRS ≥4 at baseline achieving a ≥4-point improvement in Pruritus NRS score from baseline at Week 24, 2. Absolute change from baseline in DLQI to Week 24.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 25, 2026